At the news
? NEUTRALIMPACT 5/10 PRESS-RELEASE filed Apr 20, 2026 at 16:05 ET
Trevi Therapeutics (TRVI) completed a public offering of 13.34 million shares at $13.00 per share, raising approximately $173 million in gross proceeds. The capital raise, which included full exercise of the underwriters' option for 1.74 million additional shares, will support development of its investigational therapy Haduvio for chronic cough conditions.
- Closed public offering of 13,340,000 shares at $13.00 per share
- Gross proceeds of approximately $173 million before underwriting discounts and expenses
- Underwriters fully exercised option to purchase 1,740,000 additional shares
- Proceeds to fund development of Haduvio™ (oral nalbuphine ER) for chronic cough in IPF, non-IPF ILD, and RCC
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access